MRNA

Moderna Inc. (MRNA) | Rumor.io

Moderna

MRNA

Attention (50-day avg)0.59%

Attention rank (50-day avg)#32

Bullish sentiment (50-day avg)72%

Price to earnings ratio25

Market capitalization78.8B

Earnings per share-7.98

Dividend yield (TTM)—

Revenue (annual)1.9B

Net income (annual)-2.8B

Social

What share of all stock conversation is about MRNA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.1% +0.03	0.1% +0.01	0.08% -0.74	0.08% +0.02

Sep 29

Moderna, Inc. (MRNA) has been a strong performer in the market, with some investors holding it as their best-performing stock.
The company's CEO has been vocal about not being interested in selling the company, despite big pharma's interest in the technology, which may contribute to its strong performance.
Some investors are bullish on MRNA, citing its potential for growth, particularly with the upcoming FDA approval of its cancer drug, and are advising to "buy and hold."

Generated by AI

Sentiment

Of the messages about MRNA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	63.59% -7.21	74.41% -10.81	77.09% +5.15	77.28% +30.02
Bearish	36.41% +7.21	25.59% +10.81	22.91% -5.15	22.72% -30.02

Bullish· Sep 29

Moderna's stock has been the best performing in some portfolios, with a stress-free trade trailing the 5 EMA beautifully and a repeatable setup.
The company has shown significant strength in recent weeks, with a strong possibility of surpassing $200 and $300 price targets.
Moderna's focus on prevention through its mRNA-4194 product is a hidden gem, with a strong potential for cancer prevention and a $250 short-term price target.

Bearish· Sep 29

The company's sales and earnings data suggest a lack of profitability and potential for significant losses in the foreseeable future.
Short sellers are optimistic about the asset's collapse, with some even buying more shares in anticipation of further price drops.
The current price level is considered a "falling knife" situation, where investors are likely to incur significant losses if they try to buy in now.

Generated by AI

Topics

Of the messages about MRNA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	27.27%	3.99%	2.25%	30.65%
Announcements	0%	42.33%	44.88%	17.22%
Technical Analysis	44.55%	47.16%	50.56%	2.28%
Earnings	0%	0%	0%	9.74%
Macro	27.27%	3.26%	1.95%	38.79%
Controversies	0.91%	3.26%	0.36%	1.31%

Earnings· Nov 6

Moderna reported Q3 2025 revenue of $1.02B, down 45% YoY, driven by lower COVID vaccine demand, with COVID-19 vaccine sales reaching $971M.
The company narrowed its FY25 revenue view to $1.6B-$2B from $1.5B-$2.2B, with a consensus estimate of $1.88B, and lowered its projected operating expenses.
Moderna's Q3 2025 earnings beat expectations, with a cost of sales for 2025 expected to be approximately $0.8B-$0.9B, lowered from $1.2B, and a year-end cash and investments estimate of $6.5B-$7.0B.

Analysts· Aug 20

Analysts are optimistic about Moderna's (MRNA) prospects after a successful Phase 3 trial for its cancer vaccine, with price targets raised to $89, $89, and $170 by Morgan Stanley, Morgan Stanley, and Bank of America, respectively.
Maxim views Moderna's Phase 3 melanoma study results as a "win for cancer vaccines," which should bode well for Sellas Life Sciences (SLS) on a successful Phase 3 outcome, according to a research note.
RBC Capital analyst Luca Issi believes Moderna's investment story is now "fundamentally changed" after the pivotal Phase III trial in adjuvant melanoma hit statistical significance as an add-on to Keytruda, according to a research note.

Announcements· Aug 23

Moderna's Phase 3 melanoma trial results, in combination with Keytruda, showed success in hitting recurrence-free survival endpoints, highlighting the potential of personalized mRNA cancer vaccines.
In contrast to Moderna's approach, Ibrx's CAR-NK and Anktiva platforms utilize IL-15 superagonist mechanics to rapidly expand natural killer (NK) cells and CD8+ T-cells, offering a broader immune activation strategy.
Rep. Ro Khanna faced questions over his reported purchase of Moderna stock, with some arguing it was a wise investment given the low stock price, while others criticized federal officials for trading stocks, citing a law that has not yet passed.

Controversies· Mar 4

Moderna, Inc. (MRNA) has agreed to a $950M lump-sum settlement with Arbutus and Genevant to resolve all worldwide patent litigation over COVID/mRNA vaccines.
The settlement removes a major legal overhang and could reduce long-term risk for Moderna, with the company also facing potential additional payments of up to $1.3B if appeals are unsuccessful.
Moderna's stock surged after the settlement, with shares rising over 11% after clearing a $2.25B patent overhang, and the company's CEO has stated that the deal removes a significant legal risk.

Macro· Feb 10

Auto prices have decelerated, indicating a potential decrease in demand.
This suggests the Omicron boost may have mostly run its course.
The impact on Moderna, Inc. (MRNA) could be significant due to the vaccine's relevance to the Omicron variant.

Technical Analysis· Sep 2

$MRNA has broken out of a triangle, but needs to ascend or expand aggressively to confirm the breakout.
$MRNA is facing resistance at $162.50, a break above this level could spark momentum back toward the mid-$170s, but a break below $141 support risks a slide toward the $130s.
$MRNA is flashing a powerful Elliott Wave bullish signal, with momentum building in Wave III, suggesting a potential bullish continuation trend.

Generated by AI

Community

Of the messages about MRNA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	10.75%	49.71%	50.09%	22.45%
Newcomers	89.25%	50.29%	49.91%	77.55%

Regulars· Sep 29

The Moderna stock price is experiencing a strong upward trend, with regulars noting a possible institutional buy-in and a "buy and hold" strategy.
Some participants are confident that short sellers will be finished, while others are skeptical about the company's prospects, calling it a "scam" or a "pump."
Regulars are focused on the company's potential for cancer prevention and treatment, with one user comparing it to an "endorphin machine," and another noting a possible $250 price target.

Newcomers· Sep 29

The newcomers are focused on the potential for Moderna's vaccine technology to be used in cancer treatment, with some users mentioning the connection to Keytruda, a cancer drug.
The newcomers are discussing the stock's recent performance, with some users noting its strength over the last few weeks and others predicting a potential price increase to over $200.
The newcomers are also speculating about the potential for Moderna's stock to continue its upward trend, with some users predicting a "massacre of shorts" and others warning of an imminent collapse.

Generated by AI

News

Why is Moderna stock down 4% today?

1h agoInvesting.com

Moderna Sets Another Fresh 52-Week High: What's Happening? - Moderna (NASDAQ:MRNA)

Moderna shares are climbing again Tuesday, touching a new 52-week high of $208.90 on continued momentum from strong clinical trial news.

17h agoBenzinga

Moderna And Merck: The Intismeran Readout That Was Worth $86 Billion (NASDAQ:MRNA)

Moderna stock is near the bull-case range, but the central-case implies downside. Click here to read this latest analysis of MRNA.

18h agoSeeking Alpha

Moderna stock hits 52-week high at 202.69 USD

21h agoInvesting.com

Pfizer, BioNTech, Moderna dealt blow in effort to dismiss mRNA patent lawsuits (PFE:NYSE)

Delaware judge lets Monsanto’s mRNA patent lawsuits vs Pfizer, BioNTech, and Moderna proceed. Read more here.

1d agoSeeking Alpha

Pfizer, BioNTech and Moderna lose bid to dismiss Bayer patent case

1d agoInvesting.com

Also Discussed

Investors talking about MRNA also mention

#	Name	Attention
1	BioNTech SEBNTX	0%new
2	Pfizer Inc.PFE	0.04%-0.01
3	Novavax Inc.NVAX	0.06%+0.01
4	AstraZeneca PLC American Depositary SharesAZN	0.02%+0.02
5	Arbutus Biopharma CorporationABUS	0%0
6	Merck & Co., Inc.MRK	0.01%-0.06
7	CVAC - CureVac N.V.	——
8	Johnson & JohnsonJNJ	0%-0.06
9	Vir Biotechnology, Inc.VIR	0%+0
10	Zoom Communications, Inc. Class A Common StockZM	0%+0

Moderna Inc.

Healthcare
Biotechnology

Moderna Inc. is a biotechnology company focused on developing medicines and vaccines based on messenger RNA (mRNA) technology. Its commercial portfolio includes respiratory and infectious disease vaccines, while its broader pipeline spans oncology, rare diseases, autoimmune conditions, and other therapeutic areas. Moderna uses its mRNA platform to design products that instruct cells to produce proteins or immune responses relevant to prevention and treatment. The company also works with manufacturing and commercialization capabilities to support product development and distribution across major healthcare markets. Headquartered in Cambridge, Massachusetts, Moderna plays a significant role in the biopharmaceutical industry by advancing a new class of medicines across vaccines and therapeutics.

Website

Location

325 Binney Street

Cambridge, MA, 02142

United States

Social

What share of all stock conversation is about MRNA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.1% +0.03	0.1% +0.01	0.08% -0.74	0.08% +0.02

Sep 29

Moderna, Inc. (MRNA) has been a strong performer in the market, with some investors holding it as their best-performing stock.
The company's CEO has been vocal about not being interested in selling the company, despite big pharma's interest in the technology, which may contribute to its strong performance.
Some investors are bullish on MRNA, citing its potential for growth, particularly with the upcoming FDA approval of its cancer drug, and are advising to "buy and hold."

Generated by AI

Sentiment

Of the messages about MRNA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	63.59% -7.21	74.41% -10.81	77.09% +5.15	77.28% +30.02
Bearish	36.41% +7.21	25.59% +10.81	22.91% -5.15	22.72% -30.02

Bullish· Sep 29

Moderna's stock has been the best performing in some portfolios, with a stress-free trade trailing the 5 EMA beautifully and a repeatable setup.
The company has shown significant strength in recent weeks, with a strong possibility of surpassing $200 and $300 price targets.
Moderna's focus on prevention through its mRNA-4194 product is a hidden gem, with a strong potential for cancer prevention and a $250 short-term price target.

Bearish· Sep 29

The company's sales and earnings data suggest a lack of profitability and potential for significant losses in the foreseeable future.
Short sellers are optimistic about the asset's collapse, with some even buying more shares in anticipation of further price drops.
The current price level is considered a "falling knife" situation, where investors are likely to incur significant losses if they try to buy in now.

Generated by AI

Topics

Of the messages about MRNA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	27.27%	3.99%	2.25%	30.65%
Announcements	0%	42.33%	44.88%	17.22%
Technical Analysis	44.55%	47.16%	50.56%	2.28%
Earnings	0%	0%	0%	9.74%
Macro	27.27%	3.26%	1.95%	38.79%
Controversies	0.91%	3.26%	0.36%	1.31%

Earnings· Nov 6

Moderna reported Q3 2025 revenue of $1.02B, down 45% YoY, driven by lower COVID vaccine demand, with COVID-19 vaccine sales reaching $971M.
The company narrowed its FY25 revenue view to $1.6B-$2B from $1.5B-$2.2B, with a consensus estimate of $1.88B, and lowered its projected operating expenses.
Moderna's Q3 2025 earnings beat expectations, with a cost of sales for 2025 expected to be approximately $0.8B-$0.9B, lowered from $1.2B, and a year-end cash and investments estimate of $6.5B-$7.0B.

Analysts· Aug 20

Analysts are optimistic about Moderna's (MRNA) prospects after a successful Phase 3 trial for its cancer vaccine, with price targets raised to $89, $89, and $170 by Morgan Stanley, Morgan Stanley, and Bank of America, respectively.
Maxim views Moderna's Phase 3 melanoma study results as a "win for cancer vaccines," which should bode well for Sellas Life Sciences (SLS) on a successful Phase 3 outcome, according to a research note.
RBC Capital analyst Luca Issi believes Moderna's investment story is now "fundamentally changed" after the pivotal Phase III trial in adjuvant melanoma hit statistical significance as an add-on to Keytruda, according to a research note.

Announcements· Aug 23

Moderna's Phase 3 melanoma trial results, in combination with Keytruda, showed success in hitting recurrence-free survival endpoints, highlighting the potential of personalized mRNA cancer vaccines.
In contrast to Moderna's approach, Ibrx's CAR-NK and Anktiva platforms utilize IL-15 superagonist mechanics to rapidly expand natural killer (NK) cells and CD8+ T-cells, offering a broader immune activation strategy.
Rep. Ro Khanna faced questions over his reported purchase of Moderna stock, with some arguing it was a wise investment given the low stock price, while others criticized federal officials for trading stocks, citing a law that has not yet passed.

Controversies· Mar 4

Moderna, Inc. (MRNA) has agreed to a $950M lump-sum settlement with Arbutus and Genevant to resolve all worldwide patent litigation over COVID/mRNA vaccines.
The settlement removes a major legal overhang and could reduce long-term risk for Moderna, with the company also facing potential additional payments of up to $1.3B if appeals are unsuccessful.
Moderna's stock surged after the settlement, with shares rising over 11% after clearing a $2.25B patent overhang, and the company's CEO has stated that the deal removes a significant legal risk.

Macro· Feb 10

Auto prices have decelerated, indicating a potential decrease in demand.
This suggests the Omicron boost may have mostly run its course.
The impact on Moderna, Inc. (MRNA) could be significant due to the vaccine's relevance to the Omicron variant.

Technical Analysis· Sep 2

$MRNA has broken out of a triangle, but needs to ascend or expand aggressively to confirm the breakout.
$MRNA is facing resistance at $162.50, a break above this level could spark momentum back toward the mid-$170s, but a break below $141 support risks a slide toward the $130s.
$MRNA is flashing a powerful Elliott Wave bullish signal, with momentum building in Wave III, suggesting a potential bullish continuation trend.

Generated by AI

Community

Of the messages about MRNA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	10.75%	49.71%	50.09%	22.45%
Newcomers	89.25%	50.29%	49.91%	77.55%

Regulars· Sep 29

The Moderna stock price is experiencing a strong upward trend, with regulars noting a possible institutional buy-in and a "buy and hold" strategy.
Some participants are confident that short sellers will be finished, while others are skeptical about the company's prospects, calling it a "scam" or a "pump."
Regulars are focused on the company's potential for cancer prevention and treatment, with one user comparing it to an "endorphin machine," and another noting a possible $250 price target.

Newcomers· Sep 29

The newcomers are focused on the potential for Moderna's vaccine technology to be used in cancer treatment, with some users mentioning the connection to Keytruda, a cancer drug.
The newcomers are discussing the stock's recent performance, with some users noting its strength over the last few weeks and others predicting a potential price increase to over $200.
The newcomers are also speculating about the potential for Moderna's stock to continue its upward trend, with some users predicting a "massacre of shorts" and others warning of an imminent collapse.

Generated by AI

Moderna

Social

Sep 29

Bullish· Sep 29

Bearish· Sep 29

Earnings· Nov 6

Analysts· Aug 20

Announcements· Aug 23

Controversies· Mar 4

Macro· Feb 10

Technical Analysis· Sep 2

Regulars· Sep 29

Newcomers· Sep 29

Why is Moderna stock down 4% today?

Moderna Sets Another Fresh 52-Week High: What's Happening? - Moderna (NASDAQ:MRNA)

Moderna And Merck: The Intismeran Readout That Was Worth $86 Billion (NASDAQ:MRNA)

Moderna stock hits 52-week high at 202.69 USD

Pfizer, BioNTech, Moderna dealt blow in effort to dismiss mRNA patent lawsuits (PFE:NYSE)

Pfizer, BioNTech and Moderna lose bid to dismiss Bayer patent case

Also Discussed

Moderna Inc.

Company Information

Location

Why is Moderna stock down 4% today?

Moderna Sets Another Fresh 52-Week High: What's Happening? - Moderna (NASDAQ:MRNA)

Moderna And Merck: The Intismeran Readout That Was Worth $86 Billion (NASDAQ:MRNA)

Moderna stock hits 52-week high at 202.69 USD

Pfizer, BioNTech, Moderna dealt blow in effort to dismiss mRNA patent lawsuits (PFE:NYSE)

Pfizer, BioNTech and Moderna lose bid to dismiss Bayer patent case

Also Discussed

Social

Sep 29

Bullish· Sep 29

Bearish· Sep 29

Earnings· Nov 6

Analysts· Aug 20

Announcements· Aug 23

Controversies· Mar 4

Macro· Feb 10

Technical Analysis· Sep 2

Regulars· Sep 29

Newcomers· Sep 29